<code id='B70CFE917B'></code><style id='B70CFE917B'></style>
    • <acronym id='B70CFE917B'></acronym>
      <center id='B70CFE917B'><center id='B70CFE917B'><tfoot id='B70CFE917B'></tfoot></center><abbr id='B70CFE917B'><dir id='B70CFE917B'><tfoot id='B70CFE917B'></tfoot><noframes id='B70CFE917B'>

    • <optgroup id='B70CFE917B'><strike id='B70CFE917B'><sup id='B70CFE917B'></sup></strike><code id='B70CFE917B'></code></optgroup>
        1. <b id='B70CFE917B'><label id='B70CFE917B'><select id='B70CFE917B'><dt id='B70CFE917B'><span id='B70CFE917B'></span></dt></select></label></b><u id='B70CFE917B'></u>
          <i id='B70CFE917B'><strike id='B70CFE917B'><tt id='B70CFE917B'><pre id='B70CFE917B'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:77
          The Novartis booth at ESMO in Madrid.
          The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

          MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

          The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

          advertisement

          The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Sports medicine is finally prioritizing gender equality
          Sports medicine is finally prioritizing gender equality

          MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

          read more
          Digital health: a case of mistaken identity
          Digital health: a case of mistaken identity

          AdobeHistoryandliteraturearerepletewithcautionarytalesonthedangersofpretendingtobesomeone—orsomethin

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo